1. Selective Growth Inhibition of Cancer Cells by L-Methioninase-Containing Fusion Protein Targeted to the Urokinase Receptor
- Author
-
Palwai, Naveen R., Zang, Xiao-Ping, Harrison, Roger G., Benbrook, Doris, and Pento, J. Thomas
- Subjects
Carbon-Sulfur Lyases ,Drug Delivery Systems ,Dose-Response Relationship, Drug ,Cell Movement ,Cell Survival ,Short Communication ,Cell Line, Tumor ,Recombinant Fusion Proteins ,Mutation ,Humans ,Antineoplastic Agents ,Cell Proliferation ,Receptors, Urokinase Plasminogen Activator - Abstract
We have reported the development of a novel fusion protein (FP) consisting of an amino-terminal fragment of urokinase linked to the amino terminus of the enzyme L-methioninase (L-M). The present study compared the effect of this novel FP on the proliferation of human ovarian, skin, breast endometrial and pancreatic cancer cell lines.The FP, L-M and a mutated FP, with reduced L-M activity, were produced by recombinant methods. The effect of treatment with FP, L-M and mutated FP on the proliferation of the cancer cells was measured in vitro using an MTS assay.The inhibitory effect of the FP was found to be significantly greater than that of L-M alone or the mutated FP. In addition, the FP produced a greater inhibitory effect on an ovarian cancer cell line than on comparable normal, non-cancerous cells. Further, the FP produced a dose-dependent inhibition of the proliferation of pancreatic cancer cell lines.These results suggest that this FP is a potent and selective inhibitor of the proliferation of various cancer cell lines and has potential as a therapeutic agent for the treatment of various methionine-dependent cancers.
- Published
- 2009